{"id":757208,"date":"2023-05-10T08:03:26","date_gmt":"2023-05-10T12:03:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/"},"modified":"2023-05-10T08:03:26","modified_gmt":"2023-05-10T12:03:26","slug":"zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/","title":{"rendered":"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CELEBRATION, Fla., May  10, 2023  (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc.\u00a0(NasdaqGS: ZVRA) (\u201cZevra\u201d or the \u201cCompany\u201d and formerly\u00a0KemPharm, Inc.), a rare disease therapeutics company, today announced that R. LaDuane Clifton, the Company\u2019s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET. In addition, members of Zevra\u2019s management team will be available for one-on-one investor meetings with registered attendees during the conference from May 16-17, 2023.<\/p>\n<p align=\"justify\">Clifton will discuss Zevra\u2019s unique, data-driven clinical, regulatory, and commercialization strategies to advance rare disease therapies that address areas of unmet need currently focused on idiopathic hypersomnia (IH) and Niemann-Pick type C (NPC). This in-person event will also be available live online Tuesday, May 16, 2023, from 3:05 \u2013 3:30 p.m. ET and on Zevra\u2019s website after the event.<\/p>\n<p align=\"justify\">The live webcast is available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7l3r3bFlAFgcnbeTlOFjOpfHysTI3oMa9lJqA4uR4QbdGoLiWGY0ebjjjLgqQXasaXvp5tmePwb2X1nykqUHCKX_81WYYs04qTHzi35s5N7TdJq4pxUUCB6dUZQ-MTER\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. The archived presentation will be accessible under \u201cEvents &amp; Presentations\u201d on the Investor Relations section of Zevra\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6vAdwgZ1Hpz_hwMG57RKogYZjqVD7iGlyf4tPNfp6vF6UIQjyiYbcD996_S8jcN2y_zZQPLgV6Q7zOIz42Qu8bMWRZ_H1HymrR35CFHtcLI=\" rel=\"nofollow noopener\" target=\"_blank\">investors.zevra.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Zevra<\/strong><br \/>\n        <br \/>Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. With unique, data-driven clinical, regulatory, and commercialization strategies, the Company is overcoming complex drug development challenges to bring much-needed therapies to patients.<\/p>\n<p align=\"justify\">Arimoclomol, Zevra\u2019s orally-delivered, first-in-class investigational product candidate for the treatment of Niemann-Pick disease type C (\u201cNPC\u201d), has been granted orphan drug designation, Fast Track designation, Breakthrough Therapy designation and rare pediatric disease designation for NPC by the U.S. Food and Drug Administration (\u201cFDA\u201d), and orphan medicinal product designation for the treatment of NPC by the European Medicines Agency (\u201cEMA\u201d). The arimoclomol New Drug Application (NDA) is currently being prepared for a resubmission to the FDA.<\/p>\n<p align=\"justify\">KP1077 is Zevra\u2019s lead clinical candidate being developed to treat idiopathic hypersomnia (\u201cIH\u201d) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (\u201cSDX\u201d), Zevra\u2019s proprietary prodrug of d-methylphenidate (\u201cd-MPH\u201d). The FDA has granted KP1077 orphan drug designation for the treatment of IH, and the U.S. Drug Enforcement Agency (\u201cDEA\u201d) has classified SDX as a Schedule IV controlled substance based on evidence suggesting SDX has a lower potential for abuse when compared to d-MPH, a Schedule II controlled substance.<\/p>\n<p align=\"justify\">Early access programs are made available by Zevra Therapeutics, Inc. and its affiliates and are subject to the Company&#8217;s Early Access Program (\u201cEAP\u201d) policy as published on its website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YscRneAWpfFL__xgDadz-4Wa8EpeleYmxGYGvgm42JJBcMliwAX_clytrwux__VA\" rel=\"nofollow noopener\" target=\"_blank\">zevra.com<\/a>. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician&#8217;s discretion.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Nichol Ochsner<br \/>+1 (732) 754-2545<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vRKLHmJaCpxvLybTDJVl1o3YiceaOTb7MmRLKG2OfiphIHjBroGoBwbNbgYFsL6B0H_8MS477a2WfI25ebZc0qxBN8e7Vew019C6XvOiNBo=\" rel=\"nofollow noopener\" target=\"_blank\">nochsner@zevra.com<\/a><\/p>\n<p>Janine Bogris<br \/>+1 (201) 245-6838<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0Pz8xQrqHRSTZQURsb-NcA_xi6y7kwiYNBc-ZN8Hix4P0XIXDJJBAUhwNoKgIRGcAuOFlHp2ptnu1lKV1KNVJNMAq92mt1rKNIu-7b-s37TfbnK_znupppmYC3u_335m\" rel=\"nofollow noopener\" target=\"_blank\">Janine.Bogris@canalecomm.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjU2NGI2MTAtNjRiMi00MDgyLTgyNjMtNTFiMTA1Y2M3ZjY0LTEwMjkzMjg=\/tiny\/Zevra-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc.\u00a0(NasdaqGS: ZVRA) (\u201cZevra\u201d or the \u201cCompany\u201d and formerly\u00a0KemPharm, Inc.), a rare disease therapeutics company, today announced that R. LaDuane Clifton, the Company\u2019s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET. In addition, members of Zevra\u2019s management team will be available for one-on-one investor meetings with registered attendees during the conference from May 16-17, 2023. Clifton will discuss Zevra\u2019s unique, data-driven clinical, regulatory, and commercialization strategies to advance rare disease therapies that address areas of unmet need currently focused on idiopathic hypersomnia (IH) and Niemann-Pick type C (NPC). This in-person event will also be available live online &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-757208","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc.\u00a0(NasdaqGS: ZVRA) (\u201cZevra\u201d or the \u201cCompany\u201d and formerly\u00a0KemPharm, Inc.), a rare disease therapeutics company, today announced that R. LaDuane Clifton, the Company\u2019s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET. In addition, members of Zevra\u2019s management team will be available for one-on-one investor meetings with registered attendees during the conference from May 16-17, 2023. Clifton will discuss Zevra\u2019s unique, data-driven clinical, regulatory, and commercialization strategies to advance rare disease therapies that address areas of unmet need currently focused on idiopathic hypersomnia (IH) and Niemann-Pick type C (NPC). This in-person event will also be available live online &hellip; Continue reading &quot;Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-10T12:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023\",\"datePublished\":\"2023-05-10T12:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/\"},\"wordCount\":462,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/\",\"name\":\"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=\",\"datePublished\":\"2023-05-10T12:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/","og_locale":"en_US","og_type":"article","og_title":"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023 - Market Newsdesk","og_description":"CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc.\u00a0(NasdaqGS: ZVRA) (\u201cZevra\u201d or the \u201cCompany\u201d and formerly\u00a0KemPharm, Inc.), a rare disease therapeutics company, today announced that R. LaDuane Clifton, the Company\u2019s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET. In addition, members of Zevra\u2019s management team will be available for one-on-one investor meetings with registered attendees during the conference from May 16-17, 2023. Clifton will discuss Zevra\u2019s unique, data-driven clinical, regulatory, and commercialization strategies to advance rare disease therapies that address areas of unmet need currently focused on idiopathic hypersomnia (IH) and Niemann-Pick type C (NPC). This in-person event will also be available live online &hellip; Continue reading \"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-10T12:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023","datePublished":"2023-05-10T12:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/"},"wordCount":462,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/","name":"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=","datePublished":"2023-05-10T12:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTYxMyM1NTg1MTA5IzIwMTc3NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-will-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-16-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference\u00a0on May 16, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=757208"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757208\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=757208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=757208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=757208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}